These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
92 related items for PubMed ID: 8511876
1. [Activity of 5'-nucleotidase from thymus and tumors upon administering bradykinin to tumor-bearing mice]. Sukhanova GA, Potanova GV, Narbutovich SA. Vopr Med Khim; 1993; 39(2):13-5. PubMed ID: 8511876 [Abstract] [Full Text] [Related]
2. Alterations in ribonuclease activities in the plasma, spleen, and thymus of tumor-bearing mice. Drake WP, Kopyta LP, Levy CC, Mardiney MR. Cancer Res; 1975 Feb; 35(2):322-4. PubMed ID: 1053698 [Abstract] [Full Text] [Related]
3. Immunopotentiation in mice bearing a spontaneous transplantable T-cell lymphoma: role of thymic extract. Shanker A, Singh SM. Neoplasma; 2003 Feb; 50(4):272-9. PubMed ID: 12937840 [Abstract] [Full Text] [Related]
4. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Wu J, Akaike T, Maeda H. Cancer Res; 1998 Jan 01; 58(1):159-65. PubMed ID: 9426072 [Abstract] [Full Text] [Related]
5. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors. Bustuoabad OD, di Gianni PD, Franco M, Kordon EC, Vanzulli SI, Meiss RP, Grion LC, Díaz GS, Nosetto SH, Hockl P, Lombardi MG, Pasqualini CD, Ruggiero RA. Oncol Res; 2002 Jan 01; 13(3):147-60. PubMed ID: 12549624 [Abstract] [Full Text] [Related]
6. Aminotransferase activities and involution of the thymus in rats bearing AH 130 tumors. Isohashi F, Tsukanaka K, Terada M, Nakanishi Y, Tani S, Sakamoto Y. Cancer Res; 1980 Mar 01; 40(3):877-81. PubMed ID: 6110478 [Abstract] [Full Text] [Related]
12. Characterization of thymocyte subpopulations by enzymatic markers. Livne PM, Sidi Y, Trainin N, Sperling O. Thymus; 1983 Sep 01; 5(5-6):393-7. PubMed ID: 6318405 [Abstract] [Full Text] [Related]
13. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth. Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Okazaki T, Nishihara S, Arai K, Yamaguchi S, Shibuya M, Nakaike S, Tanaka M. Cancer Chemother Pharmacol; 2004 Jul 01; 54(1):16-24. PubMed ID: 15064856 [Abstract] [Full Text] [Related]
14. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Luo JC, Toyoda M, Shibuya M. Cancer Res; 1998 Jun 15; 58(12):2594-600. PubMed ID: 9635584 [Abstract] [Full Text] [Related]
15. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo. Chen H, Takahashi S, Imamura M, Okutani E, Zhang ZG, Chayama K, Chen BA. Chin Med J (Engl); 2007 May 20; 120(10):898-904. PubMed ID: 17543180 [Abstract] [Full Text] [Related]
18. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Wang R, Zhang XW, Wang GQ, Chen XC, Tian L, Yang HS, Hu M, Peng F, Yang JL, He QM, Zhang W, Jiang Y, Deng HX, Wen YJ, Li J, Zhao X, Wei YQ. Cancer Gene Ther; 2006 Oct 20; 13(10):940-7. PubMed ID: 16799469 [Abstract] [Full Text] [Related]